Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 396,100 shares, an increase of 278.0% from the October 15th total of 104,800 shares. Based on an average trading volume of 252,700 shares, the days-to-cover ratio is currently 1.6 days. Approximately 1.9% of the company’s shares are sold short.

Xilio Therapeutics Stock Down 0.9 %

Shares of XLO stock opened at $1.08 on Wednesday. The firm has a 50 day moving average of $0.89 and a 200-day moving average of $0.95. The company has a market cap of $47.47 million, a price-to-earnings ratio of -0.62 and a beta of -0.24. Xilio Therapeutics has a 52 week low of $0.49 and a 52 week high of $1.93.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xilio Therapeutics stock. Renaissance Technologies LLC lifted its stake in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 295,000 shares of the company’s stock after purchasing an additional 45,554 shares during the quarter. Renaissance Technologies LLC owned about 0.80% of Xilio Therapeutics worth $280,000 at the end of the most recent reporting period. Institutional investors own 54.29% of the company’s stock.

Analyst Ratings Changes

Separately, Raymond James decreased their price objective on Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a report on Friday, November 8th.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.